​​​​​​​PEG-BIO Biopharm Co.,Ltd(chongqing).
News Center
Home >> 行业动态 >> Know yourself and Know your Rivals: Here's a look at the Japanese pharmaceutical industry
Know yourself and Know your Rivals: Here's a look at the Japanese pharmaceutical industry
Source:药事纵横 | Author:pro954f45 | Published time: 2018-03-02 | 1477 Views | Share:


      Japan's second tier of pharmaceutical companies includes Kirin, Chinadiogo, Tanabe Mitsubishi and Sumitomo, which were once among the world's top 50 companies. China Pharma is controlled by Roche, and the pipeline of biological products research and development is very strong, especially in the field of monoclonal antibodies. Kirin is also good at biological products. A number of monoclonal antibodies in the r&d pipeline have entered the harvest stage, while Tanabe Mitsubishi has the star product Kagerazine, sumitomo has Meropenem... The third tier of Japanese pharmaceutical companies had sales of between $1bn and $3bn in 2016. Many pharmaceutical companies in this echelon also have strong research and development capabilities. Yanoyi's antiviral, Onokazu's PD-1 monoclonal antibody, Shentian's ophthalmic medication, and Changguang's transdermal patch are all well known around the world.
      Many Japanese pharmaceutical enterprises, especially the second and third echelons, share a similar characteristic. Most of them started their business through the development of ME TOO products after 1990s, and quickly became rich through one or several new drugs. Within a short decade, they became one of the top 50 pharmaceutical companies in the world. But as FDA approvals for ME TOO products tightened and "cash cow" patents expired, their sales and profits began to decline. Therefore, compared with traditional pharmaceutical giants such as Pfizer and Novartis, Japanese pharmaceutical companies are mostly "rising stars" with poor ability to resist the risks of patent cliff.